At a glance
- Originator Meiji Seika Kaisha
- Class Anti-ischaemics; Antiplatelets; Vascular disorder therapies
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemia
Most Recent Events
- 10 Nov 2006 Discontinued - Preclinical for Ischaemia in Japan (unspecified route)
- 15 Sep 1999 New profile
- 15 Sep 1999 Preclinical development for Ischaemia in Japan (Unknown route)